Skip to content
2000
Volume 11, Issue 1
  • ISSN: 2405-4615
  • E-ISSN: 2405-4623

Abstract

Parkinson's Disease (PD) is a neurodegenerative syndrome defined by the deterioration of dopamine neurons, showing a loss of motor activity. The treatment of PD is still challenging despite the development of numerous management techniques. Blood-brain Barrier (BBB) provides limited access to drug transport, being a major limiting factor in the treatment of Central Nervous System (CNS) disorders. Further, the major challenges in neurodegenerative diseases are low bioavailability and side effects. Intranasal drug delivery has become increasingly accessible for the treatment of several CNS disorders, including PD. The nasal cavity has direct access to the brain and drugs may be delivered at the site of action by bypassing the blood-brain barrier. Therapeutic molecules could be directly delivered to the brain through the olfactory region in the nasal cavity; further, the first-pass effects of drugs could also be eliminated. Several novel and promising developments in non-invasive approaches have been revealed for brain targeting by the nasal route. Among them, Nanoemulsions (NEs)-based drug delivery has been most widely explored, which can assist in several significant issues, such as limited BBB permeability, limited solubility, poor bioavailability, limited onset of action, and less enzymatic degradation. Several research reports have indicated intranasal NEs to have potential brain-targeting abilities, which may be widely explored for the treatment of PD. Therefore, the present review article has focused on the current scenario of intranasal NEs for the management of PD, with recent outcomes outlined through various research studies.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnm/10.2174/0124054615343935240918053255
2024-09-22
2026-02-26

  • From This Site

    /content/journals/cnm/10.2174/0124054615343935240918053255
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ObesoJ.A. StamelouM. GoetzC.G. PoeweW. LangA.E. WeintraubD. BurnD. HallidayG.M. BezardE. PrzedborskiS. LehericyS. BrooksD.J. RothwellJ.C. HallettM. DeLongM.R. MarrasC. TannerC.M. RossG.W. LangstonJ.W. KleinC. BonifatiV. JankovicJ. LozanoA.M. DeuschlG. BergmanH. TolosaE. Rodriguez-ViolanteM. FahnS. PostumaR.B. BergD. MarekK. StandaertD.G. SurmeierD.J. OlanowC.W. KordowerJ.H. CalabresiP. SchapiraA.H.V. StoesslA.J. Past, present, and future of Parkinson’s disease: A special essay on the 200th Anniversary of the Shaking Palsy.Mov. Disord.20173291264131010.1002/mds.2711528887905
     [Google Scholar]
  2. RossiA. BergerK. ChenH. LeslieD. MailmanR.B. HuangX. Projection of the prevalence of Parkinson’s disease in the coming decades: Revisited.Mov. Disord.201833115615910.1002/mds.2706328590580
     [Google Scholar]
  3. HirschL. JetteN. FrolkisA. SteevesT. PringsheimT. The incidence of Parkinson’s disease: A systematic review and meta-analysis.Neuroepidemiology201646429230010.1159/00044575127105081
     [Google Scholar]
  4. Ben-ShlomoY. DarweeshS. Llibre-GuerraJ. MarrasC. San LucianoM. TannerC. The epidemiology of Parkinson’s disease.Lancet20244031042328329210.1016/S0140‑6736(23)01419‑838245248
     [Google Scholar]
  5. DarweeshS.K.L. KoudstaalP.J. StrickerB.H. HofmanA. IkramM.A. Trends in the incidence of Parkinson disease in the general population.Am. J. Epidemiol.2016183111018102610.1093/aje/kwv27127188952
     [Google Scholar]
  6. DorseyE.R. ElbazA. NicholsE. AbbasiN. Abd-AllahF. AbdelalimA. AdsuarJ.C. AnshaM.G. BrayneC. ChoiJ-Y.J. Collado-MateoD. DahodwalaN. DoH.P. EdessaD. EndresM. FereshtehnejadS-M. ForemanK.J. GankpeF.G. GuptaR. HamidiS. HankeyG.J. HayS.I. HegazyM.I. HibstuD.T. KasaeianA. KhaderY. KhalilI. KhangY-H. KimY.J. KokuboY. LogroscinoG. MassanoJ. Mohamed IbrahimN. MohammedM.A. MohammadiA. Moradi-LakehM. NaghaviM. NguyenB.T. NirayoY.L. OgboF.A. OwolabiM.O. PereiraD.M. PostmaM.J. QorbaniM. RahmanM.A. RobaK.T. SafariH. SafiriS. SatpathyM. SawhneyM. ShafieesabetA. ShiferawM.S. SmithM. SzoekeC.E.I. Tabarés-SeisdedosR. TruongN.T. UkwajaK.N. VenketasubramanianN. VillafainaS. weldegwergsK. WestermanR. WijeratneT. WinklerA.S. XuanB.T. YonemotoN. FeiginV.L. VosT. MurrayC.J.L. GBD 2016 Parkinson’s Disease Collaborators Global, regional, and national burden of Parkinson’s disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016.Lancet Neurol.2018171193995310.1016/S1474‑4422(18)30295‑330287051
     [Google Scholar]
  7. MarrasC. LangA. van de WarrenburgB.P. SueC.M. TabriziS.J. BertramL. Mercimek-MahmutogluS. Ebrahimi-FakhariD. WarnerT.T. DurrA. AssmannB. LohmannK. KosticV. KleinC. Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.Mov. Disord.201631443645710.1002/mds.2652727079681
     [Google Scholar]
  8. ZhangW. ZhaoX. BhuiyanP. LiuH. WeiH. Neuroprotective effects of dantrolene in neurodegenerative disease: Role of inhibition of pathological inflammation.J Anasth and Trans Med202432273510.1016/j.jatmed.2024.04.00238826587
     [Google Scholar]
  9. AscherioA. SchwarzschildM.A. The epidemiology of Parkinson’s disease: Risk factors and prevention.Lancet Neurol.201615121257127210.1016/S1474‑4422(16)30230‑727751556
     [Google Scholar]
  10. BreckenridgeC.B. BerryC. ChangE.T. SielkenR.L.Jr MandelJ.S. Association between Parkinson’s disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: systematic review and meta-analysis.PLoS One2016114e015184110.1371/journal.pone.015184127055126
     [Google Scholar]
  11. ArmstrongM.J. OkunM.S. Diagnosis and treatment of Parkinson disease.JAMA2020323654856010.1001/jama.2019.2236032044947
     [Google Scholar]
  12. BergD. PostumaR.B. AdlerC.H. BloemB.R. ChanP. DuboisB. GasserT. GoetzC.G. HallidayG. JosephL. LangA.E. Liepelt-ScarfoneI. LitvanI. MarekK. ObesoJ. OertelW. OlanowC.W. PoeweW. SternM. DeuschlG. MDS research criteria for prodromal Parkinson’s disease.Mov. Disord.201530121600161110.1002/mds.2643126474317
     [Google Scholar]
  13. ChenY. ZhangC. HuangY. MaY. SongQ. ChenH. JiangG. GaoX. Intranasal drug delivery: The interaction between nanoparticles and the nose-to-brain pathway.Adv. Drug Deliv. Rev.202420711519610.1016/j.addr.2024.11519638336090
     [Google Scholar]
  14. YanamadalaY. RoyR. WilliamsA.A. UppuN. KimA.Y. DeCosterM.A. KimP. MurrayT.A. Intranasal delivery of cell-penetrating therapeutic peptide enhances brain delivery, reduces inflammation, and improves neurologic function in moderate traumatic brain injury.Pharmaceutics202416677410.3390/pharmaceutics1606077438931895
     [Google Scholar]
  15. CheraitA. BanksW.A. VaudryD. The potential of the nose- to-brain delivery of PACAP for the treatment of neuronal disease.Pharmaceutics2023158203210.3390/pharmaceutics1508203237631246
     [Google Scholar]
  16. KumarM. NishadD.K. KumarA. BhatnagarA. KarwasraR. KhannaK. SK. SharmaD. DuaK. MudaliyarV. SharmaN. Enhancement in brain uptake of vitamin D3 nanoemulsion for treatment of cerebral ischemia: formulation, gamma scintigraphy and efficacy study in transient middle cerebral artery occlusion rat models.J. Microencapsul.202037749250110.1080/02652048.2020.180187032715833
     [Google Scholar]
  17. SharmaA. SharmaN. SinghS. DuaK. Review on theranostic and neuroprotective applications of nanotechnology in multiple sclerosis.J. Drug Deliv. Sci. Technol.20238110422010.1016/j.jddst.2023.104220
     [Google Scholar]
  18. SharmaN. TyagiS. GuptaS.K. KulkarniG.T. BhatnagarA. KumarN. Development and gamma-scintigraphy study of Hibiscus rosasinensis polysaccharide-based microspheres for nasal drug delivery.Drug Dev. Ind. Pharm.201642111763177110.3109/03639045.2016.117305027032438
     [Google Scholar]
  19. KhannaK. SharmaD. KarwasraR. SharmaN. NishadD.K. PopliH. BhatnagarA. Intranasal nalbuphine formulation for faster management of pain in prehospital scenario; its safety and comparative efficacy in animal models.India J Pharma Edu and Res202054231032210.5530/ijper.54.2.36
     [Google Scholar]
  20. SinghY. MeherJ.G. RavalK. KhanF.A. ChaurasiaM. JainN.K. ChourasiaM.K. Nanoemulsion: Concepts, development and applications in drug delivery.J. Control. Release2017252284910.1016/j.jconrel.2017.03.00828279798
     [Google Scholar]
  21. OuZ. PanJ. TangS. DuanD. YuD. NongH. WangZ. Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson’s Disease in 204 Countries/Territories From 1990 to 2019.Front. Public Health2021977684710.3389/fpubh.2021.77684734950630
     [Google Scholar]
  22. PriyaS. KolandM. KumariS. Nanoemulsion components screening of quetiapine fumarate: Effect of surfactant and co surfactant.Asian J. Pharm. Clin. Res.201586136140
     [Google Scholar]
  23. LoC.H. ZengJ. Defective lysosomal acidification: A new prognostic marker and therapeutic target for neurodegenerative diseases.Transl. Neurodegener.20231212910.1186/s40035‑023‑00362‑037287072
     [Google Scholar]
  24. BrouillardM. KinetR. JoyeuxM. DehayB. Crauste-MancietS. DesvergnesV. Modulating lysosomal ph through innovative multimerized succinic acid-based nucleolipid derivatives.Bioconjug. Chem.202334357258010.1021/acs.bioconjchem.3c0004136853958
     [Google Scholar]
  25. BourdenxM. DanielJ. GeninE. SoriaF.N. Blanchard-DesceM. BezardE. DehayB. Nanoparticles restore lysosomal acidification defects: Implications for Parkinson and other lysosomal-related diseases.Autophagy201612347248310.1080/15548627.2015.113676926761717
     [Google Scholar]
  26. QuickJ.D. SilvaC. WongJ.H. LimK.L. ReynoldsR. BarronA.M. ZengJ. LoC.H. Lysosomal acidification dysfunction in microglia: An emerging pathogenic mechanism of neuroinflammation and neurodegeneration.J. Neuroinflammation202320118510.1186/s12974‑023‑02866‑y37543564
     [Google Scholar]
  27. KatareP. Pawar MedheT. NadkarniA. DeshpandeM. TekadeR.K. BenivalD. JainA. Nasal drug delivery system and devices: An overview on health effects.J. Chem. Health Saf.202431212714310.1021/acs.chas.3c00069
     [Google Scholar]
  28. Giraldo-BerrioD. Mendivil-PerezM. Velez-PardoC. Jimenez-Del-RioM. Rotenone induces a neuropathological phenotype in cholinergic-like neurons resembling Parkinson’s disease dementia (PDD).Neurotox. Res.20244232810.1007/s12640‑024‑00705‑338842585
     [Google Scholar]
  29. BridiJ.C. HirthF. Mechanisms of α-synuclein induced synaptopathy in Parkinson’s disease.Front. Neurosci.2018128010.3389/fnins.2018.0008029515354
     [Google Scholar]
  30. BraakH. Del TrediciK. Neuropathological staging of brain pathology in sporadic Parkinson’s disease: Separating the wheat from the chaff.J. Parkinsons Dis.20177s1S71S8510.3233/JPD‑17900128282810
     [Google Scholar]
  31. KouliA. TorsneyK.M. KuanW.L. Parkinson’s disease: Etiology, neuropathology, and pathogenesis. in Parkinson’s disease: Pathogenesis and clinical aspects.Brisbane, AustraliaCodon Publications201832610.15586/codonpublications.parkinsonsdisease.2018.ch1
     [Google Scholar]
  32. SurmeierD.J. ObesoJ.A. HallidayG.M. Parkinson’s disease is not simply a prion disorder.J. Neurosci.201737419799980710.1523/JNEUROSCI.1787‑16.201729021297
     [Google Scholar]
  33. GiguèreN. Burke NanniS. TrudeauL.E. On cell loss and selective vulnerability of neuronal populations in Parkinson’s disease.Front. Neurol.2018945510.3389/fneur.2018.0045529971039
     [Google Scholar]
  34. JingX.Z. YuanX.Z. LuoX. ZhangS.Y. WangX.P. An update on nondopaminergic treatments for motor and non-motor symptoms of Parkinson’s disease.Curr. Neuropharmacol.20232181806182610.2174/1570159X2066622022215081135193486
     [Google Scholar]
  35. Durmaz CelikN. OzbenS. OzbenT. Unveiling Parkinson’s disease through biomarker research: Current insights and future prospects.Crit. Rev. Clin. Lab. Sci.202411710.1080/10408363.2024.233147138529882
     [Google Scholar]
  36. LaffleurF. BauerB. Progress in nasal drug delivery systems.Int. J. Pharm.202160712099410.1016/j.ijpharm.2021.12099434390810
     [Google Scholar]
  37. DhimanV. MenonG. KaurS. MishraA. JohnD. Rao VishnuM. TiwariR. DhaliwalR. A systematic review and meta-analysis of prevalence of epilepsy, dementia, headache, and parkinson disease in India.Neurol. India202169229430110.4103/0028‑3886.31458833904437
     [Google Scholar]
  38. MoinuddinS. RazviS.M.H. UddinM.S. FazilM. Nasal drug delivery system: A innovative approach.The Pharma Innov. J.201983169177
     [Google Scholar]
  39. PandeyJ. ShankarR. KumarM. ShuklaK. KumariB. Development of nasal mucoadhesive microspheres of granisetron: A potential drug.Drug Res. (Stuttg.)202070836710.1055/a‑1193‑478132559774
     [Google Scholar]
  40. SuryanarayanaR. VinukondaA. SarojS. JainN. PandeyH. RudrabhatlaV.S.A.P. GodeT. Statistically optimized facile development, characterization and evaluation of niosomal nasal drug delivery system of ropinirole hydrochloride: In vitro drug release, cytotoxicity and ex vivo permeability studies.Int. J. Pharm. Edu. Res.2023571627310.5530/001954641874
     [Google Scholar]
  41. KumarA. GargT. SarmaG.S. RathG. GoyalA.K. Optimization of combinational intranasal drug delivery system for the management of migraine by using statistical design.Eur. J. Pharm. Sci.20157014015110.1016/j.ejps.2015.01.01225676136
     [Google Scholar]
  42. ShahP. SaroliaJ. VyasB. WaghP. AnkurK. KumarM.A. PLGA nanoparticles for nose to brain delivery of Clonazepam: Formulation, optimization by 32 Factorial design, in vitro and in vivo evaluation.Curr. Drug Deliv.202118680582410.2174/18755704MTA3lOTgqw32640955
     [Google Scholar]
  43. DjekicL. Novel mucoadhesive polymers for nasal drug delivery. Nasal Drug Delivery. PathakY.V. YadavH.K.S. ChamSpringer202310.1007/978‑3‑031‑23112‑4_11
     [Google Scholar]
  44. QuintanaD.S. WestlyeL.T. AlnæsD. RustanØ.G. KaufmannT. SmerudK.T. MahmoudR.A. DjupeslandP.G. AndreassenO.A. Low dose intranasal oxytocin delivered with breath powered device dampens amygdala response to emotional stimuli: A peripheral effect-controlled within-subjects randomized dose-response fMRI trial.Psychoneuroendocrinology20166918018810.1016/j.psyneuen.2016.04.01027107209
     [Google Scholar]
  45. WongC.Y.J. BaldelliA. HoyosC.M. TietzO. OngH.X. TrainiD. Insulin delivery to the brain via the nasal route: Unraveling the potential for Alzheimer’s disease therapy.Drug Deliv. Transl. Res.20241471776179310.1007/s13346‑024‑01558‑138441832
     [Google Scholar]
  46. BonferoniM.C. RossiS. SandriG. FerrariF. GaviniE. RassuG. GiunchediP. Nanoemulsions for “Nose-to-Brain” drug delivery.Pharmaceutics20191128410.3390/pharmaceutics1102008430781585
     [Google Scholar]
  47. SonvicoF. ClementinoA. ButtiniF. ColomboG. PescinaS. Stanisçuaski GuterresS. Raffin PohlmannA. NicoliS. Surface-modified nanocarriers for nose-to-brain delivery: From bioadhesion to targeting.Pharmaceutics20181013410.3390/pharmaceutics1001003429543755
     [Google Scholar]
  48. KulkarniM. PatelK. PatelA. PatelS. DesaiJ. PatelM. ShahU. PatelA. SolankiN. Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review.ADMET DMPK20231216310510.5599/admet.204338560713
     [Google Scholar]
  49. FormicaM.L. RealD.A. PicchioM.L. CatlinE. DonnellyR.F. ParedesA.J. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles.Appl. Mater. Today20222910163110.1016/j.apmt.2022.101631
     [Google Scholar]
  50. AlabsiW. EedaraB.B. Encinas-BasurtoD. PoltR. MansourH.M. Nose-to-brain delivery of therapeutic peptides as nasal aerosols.Pharmaceutics2022149187010.3390/pharmaceutics1409187036145618
     [Google Scholar]
  51. MartinsP.P. SmythH.D.C. CuiZ. Strategies to facilitate or block nose-to-brain drug delivery.Int. J. Pharm.201957011863510.1016/j.ijpharm.2019.11863531445062
     [Google Scholar]
  52. CamaE.S. CatenacciL. PerteghellaS. SorrentiM. CairaM.R. RassuG. GaviniE. GiunchediP. BonferoniM.C. Design and development of a chitosan-based nasal powder of dimethyl fumarate-cyclodextrin binary systems aimed at nose-to-brain administration. A stability study.Int. J. Pharm.202465912421610.1016/j.ijpharm.2024.12421638734272
     [Google Scholar]
  53. QuintanaD.S. GuastellaA.J. WestlyeL.T. AndreassenO.A. The promise and pitfalls of intranasally administering psychopharmacological agents for the treatment of psychiatric disorders.Mol. Psychiatry2016211293810.1038/mp.2015.16626552590
     [Google Scholar]
  54. CassanoR. ServidioC. TrombinoS. Biomaterials for drugs nose–brain transport: A new therapeutic approach for neurological diseases.Materials (Basel)2021147180210.3390/ma1407180233917404
     [Google Scholar]
  55. AgrawalM. SarafS. SarafS. AntimisiarisS.G. ChouguleM.B. ShoyeleS.A. AlexanderA. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.J. Control. Release201828113917710.1016/j.jconrel.2018.05.01129772289
     [Google Scholar]
  56. RaiG. GaubaP. DangS. Recent advances in nanotechnology for Intra-nasal drug delivery and clinical applications.J. Drug Deliv. Sci. Technol.20238610472610.1016/j.jddst.2023.104726
     [Google Scholar]
  57. GuptaS. KesarlaR. OmriA. Approaches for CNS delivery of drugs – nose to brain targeting of antiretroviral agents as a potential attempt for complete elimination of major reservoir site of HIV to aid AIDS treatment.Expert Opin. Drug Deliv.201916328730010.1080/17425247.2019.158320630779602
     [Google Scholar]
  58. SamaridouE. AlonsoM.J. Nose-to-brain peptide delivery – the potential of nanotechnology.Bioorg. Med. Chem.201826102888290510.1016/j.bmc.2017.11.00129170026
     [Google Scholar]
  59. CroweT.P. HsuW.H. Evaluation of recent intranasal drug delivery systems to the central nervous system.Pharmaceutics202214362910.3390/pharmaceutics1403062935336004
     [Google Scholar]
  60. PardeshiC.V. SonawaneR.O. BachhavY. TekadeA. Nanoparticles for direct nose-to-brain delivery of drugs.Int. J. Pharm.2021379114615710.1016/B978‑0‑12‑822522‑6.00008‑4
     [Google Scholar]
  61. FengY. HeH. LiF. LuY. QiJ. WuW. An update on the role of nanovehicles in nose-to-brain drug delivery.Drug Discov. Today20182351079108810.1016/j.drudis.2018.01.00529330120
     [Google Scholar]
  62. JeongS.H. JangJ.H. LeeY.B. Drug delivery to the brain via the nasal route of administration: Exploration of key targets and major consideration factors.J. Pharm. Investig.202353111915210.1007/s40005‑022‑00589‑535910081
     [Google Scholar]
  63. XieZ. ChenX. Healthy benefits and edible delivery systems of resveratrol: A review.Food Rev. Int.20233973879390510.1080/87559129.2021.2013873
     [Google Scholar]
  64. SavaleS. MahajanH. Nose to brain: A versatile mode of drug delivery system.Asian J. Biomater. Res.201731638
     [Google Scholar]
  65. AshaoluT.J. Nanoemulsions for health, food, and cosmetics: A review.Environ. Chem. Lett.20211943381339510.1007/s10311‑021‑01216‑933746662
     [Google Scholar]
  66. PandeyM. ChoudhuryH. YeunO.C. YinH.M. LynnT.W. TineC.L.Y. WiN.S. YenK.C.C. PhingC.S. KesharwaniP. BhattamisraS.K. GorainB. Perspectives of nanoemulsion strategies in the improvement of oral, parenteral and transdermal chemotherapy.Curr. Pharm. Biotechnol.201819427629210.2174/138920101966618060512523429874994
     [Google Scholar]
  67. ToksoyM.O. AşırF. GüzelM.C. Quality by design approach for development and characterization of gabapentin-loaded solid lipid nanoparticles for intranasal delivery: In vitro, ex vivo, and histopathological evaluation.Iran. J. Basic Med. Sci.202427790491310.22038/IJBMS.2024.76281.1651138800014
     [Google Scholar]
  68. PifferiF. LaurentB. PlourdeM. Lipid transport and metabolism at the blood-brain interface: Implications in health and disease.Front. Physiol.20211264564610.3389/fphys.2021.64564633868013
     [Google Scholar]
  69. Che MarzukiN.H. WahabR.A. Abdul HamidM. An overview of nanoemulsion: Concepts of development and cosmeceutical applications.Biotechnol. Biotechnol. Equip.201933177979710.1080/13102818.2019.1620124
     [Google Scholar]
  70. KhuntD. ShahB. MisraM. Role of butter oil in brain targeted delivery of Quetiapine fumarate microemulsion via intranasal route.J. Drug Deliv. Sci. Technol.201740112010.1016/j.jddst.2017.05.004
     [Google Scholar]
  71. MisraS.K. PathakK. Nose-to-brain targeting via nanoemulsion: Significance and evidence.Colloids and Interfaces2023712310.3390/colloids7010023
     [Google Scholar]
  72. LiY. LiJ. ZhangX. DingJ. MaoS. Non-ionic surfactants as novel intranasal absorption enhancers: In vitro and in vivo characterization.Drug Deliv.20162372272227910.3109/10717544.2014.97119625347689
     [Google Scholar]
  73. ChatterjeeB. GorainB. MohananaiduK. SenguptaP. MandalU.K. ChoudhuryH. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges.Int. J. Pharm.201956525826810.1016/j.ijpharm.2019.05.03231095983
     [Google Scholar]
  74. AhmadF. KaranA. SharmaR. SharmaN.S. SundarV. JayarajR. MukherjeeS. DeCosterM.A. Evolving therapeutic interventions for the management and treatment of Alzheimer’s disease.Ageing Res. Rev.20249510222910.1016/j.arr.2024.10222938364913
     [Google Scholar]
  75. KuncahyoI. ChoiriS. FudholiA. MartienR. RohmanA. Development of pitavastatin-loaded super-saturable self-nano emulsion: A continues screening and optimization approach using statistical technique.J. Dispers. Sci. Technol.202344460861710.1080/01932691.2021.1957922
     [Google Scholar]
  76. WilsonR.J. LiY. YangG. ZhaoC.X. Nanoemulsions for drug delivery.Particuology202264859710.1016/j.partic.2021.05.009
     [Google Scholar]
  77. SinghD. KapahiH. RashidM. PrakashA. MajeedA.B.A. MishraN. Recent prospective of surface engineered nanoparticles in the management of neurodegenerative disorders.Artif. Cells Nanomed. Biotechnol.201544311210.3109/21691401.2015.102962226107112
     [Google Scholar]
  78. NiraleP. PaulA. YadavK.S. Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer’s, Parkinson’s and Prion’s.Life Sci.202024511739410.1016/j.lfs.2020.11739432017870
     [Google Scholar]
  79. BhattacharyyaK.B. The story of levodopa.Ann. Indian Acad. Neurol.202225112413010.4103/aian.aian_474_2135342258
     [Google Scholar]
  80. ZainolS. BasriM. BasriH.B. ShamsuddinA.F. Abdul-GaniS.S. KarjibanR.A. Abdul-MalekE. Formulation optimization of a palm-based nanoemulsion system containing levodopa.Int. J. Mol. Sci.20121310130491306410.3390/ijms13101304923202937
     [Google Scholar]
  81. PangeniR. SharmaS. MustafaG. AliJ. BabootaS. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson’s disease by reducing oxidative stress.Nanotechnology2014254848510210.1088/0957‑4484/25/48/48510225392203
     [Google Scholar]
  82. Ramires JúniorO.V. AlvesB.S. BarrosP.A.B. RodriguesJ.L. FerreiraS.P. MonteiroL.K.S. AraújoG.M.S. FernandesS.S. VazG.R. DoraC.L. HortM.A. Nanoemulsion improves the neuroprotective effects of curcumin in an experimental model of Parkinson’s disease.Neurotox. Res.202139378779910.1007/s12640‑021‑00362‑w33860897
     [Google Scholar]
  83. MustafaG. BabootaS. AhujaA. AliJ. Formulation development of chitosan coated intra nasal ropinirole nanoemulsion for better management option of parkinson: An in vitro ex vivo evaluation.Curr. Nanosci.20128334836010.2174/157341312800620331
     [Google Scholar]
  84. AhmadE. FengY. QiJ. FanW. MaY. HeH. XiaF. DongX. ZhaoW. LuY. WuW. Evidence of nose-to-brain delivery of nanoemulsions: Cargoes but not vehicles.Nanoscale2017931174118310.1039/C6NR07581A28009915
     [Google Scholar]
  85. McAfeeD.A. HadgraftJ. LaneM.E. Rotigotine: The first new chemical entity for transdermal drug delivery.Eur. J. Pharm. Biopharm.201488358659310.1016/j.ejpb.2014.08.00725173087
     [Google Scholar]
  86. KumarM. PathakK. MisraA. Formulation and characterization of nanoemulsion-based drug delivery system of risperidone.Drug Dev. Ind. Pharm.200935438739510.1080/0363904080236370419016058
     [Google Scholar]
  87. HosnyK.M. Development of saquinavir mesylate nanoemulsion-loaded transdermal films: Two-step optimization of permeation parameters, characterization, and ex vivo and in vivo evaluation.Int. J. Nanomedicine2019148589860110.2147/IJN.S23074731802871
     [Google Scholar]
  88. MdS. AlhakamyN.A. AldawsariH.M. HusainM. KottaS. AbdullahS.T. A FahmyU. AlfalehM.A. AsfourH.Z. Formulation design, statistical optimization, and in vitro evaluation of a naringenin nanoemulsion to enhance apoptotic activity in A549 lung cancer cells.Pharmaceuticals (Basel)202013715210.3390/ph1307015232679917
     [Google Scholar]
  89. MadhusudanR.Y. ShailajaM. RamakrishnaS. RameshG. ReddyK.H. DiwanP.V. Development of olanzapine nano-emulsion for enhanced brain delivery.Int J Pharm Sci and Nanotech2012511648165910.37285/ijpsn.2012.5.1.9
     [Google Scholar]
  90. KumarS. DangS. NigamK. AliJ. BabootaS. Selegiline nanoformulation in attenuation of oxidative stress and upregulation of dopamine in the brain for the treatment of Parkinson’s disease.Rejuvenation Res.201821546447610.1089/rej.2017.203529717617
     [Google Scholar]
  91. NehalN. NabiB. RehmanS. PathakA. IqubalA. KhanS.A. YarM.S. ParvezS. BabootaS. AliJ. Chitosan coated synergistically engineered nanoemulsion of ropinirole and nigella oil in the management of Parkinson’s disease: Formulation perspective and in vitro and in vivo assessment.Int. J. Biol. Macromol.202116760561910.1016/j.ijbiomac.2020.11.20733278450
     [Google Scholar]
  92. MazzantiG. Di GiacomoS. Curcumin and resveratrol in the management of cognitive disorders: What is the clinical evidence?Molecules2016219124310.3390/molecules2109124327649135
     [Google Scholar]
  93. ChoudhuryH. ZakariaN.F.B. TilangP.A.B. TzeyungA.S. PandeyM. ChatterjeeB. AlhakamyN.A. BhattamishraS.K. KesharwaniP. GorainB. MdS. Formulation development and evaluation of rotigotine mucoadhesive nanoemulsion for intranasal delivery.J. Drug Deliv. Sci. Technol.20195410130110.1016/j.jddst.2019.101301
     [Google Scholar]
  94. KimB.H. YuK.S. JangI.J. Soo LimK. KimJ.R. ElshoffJ.P. AndreasJ.O. BraunM. CawelloW. Pharmacokinetic properties and tolerability of rotigotine transdermal patch after repeated-dose application in healthy Korean volunteers.Clin. Ther.201537490291210.1016/j.clinthera.2015.01.01325791613
     [Google Scholar]
  95. KumarM. MisraA. BabbarA.K. MishraA.K. MishraP. PathakK. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone.Int. J. Pharm.20083581-228529110.1016/j.ijpharm.2008.03.02918455333
     [Google Scholar]
  96. ĐorđevićS.M. SantračA. CekićN.D. MarkovićB.D. DivovićB. IlićT.M. SavićM.M. SavićS.D. Parenteral nanoemulsions of risperidone for enhanced brain delivery in acute psychosis: Physicochemical and in vivo performances.Int. J. Pharm.2017533242143010.1016/j.ijpharm.2017.05.05128552767
     [Google Scholar]
  97. MahajanH.S. MahajanM.S. NerkarP.P. AgrawalA. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.Drug Deliv.201421214815410.3109/10717544.2013.83801424128122
     [Google Scholar]
  98. HosnyK.M. Nanosized cubosomal thermogelling dispersion loaded with saquinavir mesylate to improve its bioavailability: Preparation, optimization, in vitro and in vivo evaluation.Int. J. Nanomedicine2020155113512910.2147/IJN.S26185532764940
     [Google Scholar]
  99. GabaB. KhanT. HaiderM.F. AlamT. BabootaS. ParvezS. AliJ. VitaminE. Vitamin E loaded naringenin nanoemulsion via intranasal delivery for the management of oxidative stress in a 6-ohda Parkinson’s disease model.BioMed Res. Int.2019201912010.1155/2019/238256331111044
     [Google Scholar]
  100. YeoE. Yew ChiengC.J. ChoudhuryH. PandeyM. GorainB. Tocotrienols-rich naringenin nanoemulgel for the management of diabetic wound: Fabrication, characterization and comparative in vitro evaluations.Curr Res Pharmacol Drug Discov2021210001910.1016/j.crphar.2021.10001934909654
     [Google Scholar]
  101. LallS. Intranasal route for brain targeting of Naringenin-a potential antioxidant drug for the treatment of Parkinson’s disease using nano-emulsion as the drug delivery carrier.Natural Volatiles & Essential OILS20207110511310.52783/nveo.5453
     [Google Scholar]
  102. KumarM. MisraA. MishraA.K. MishraP. PathakK. Mucoadhesive nanoemulsion-based intranasal drug delivery system of olanzapine for brain targeting.J. Drug Target.2008161080681410.1080/1061186080247650418988064
     [Google Scholar]
  103. KumarM. MisraA. PathakK. Formulation and characterization of nanoemulsion of olanzapine for intranasal delivery.PDA J. Pharm. Sci. Technol.200963650151120169856
     [Google Scholar]
  104. KumarS. AliJ. BabootaS. Design Expert® supported optimization and predictive analysis of selegiline nanoemulsion via the olfactory region with enhanced behavioural performance in Parkinson’s disease.Nanotechnology2016274343510110.1088/0957‑4484/27/43/43510127655136
     [Google Scholar]
  105. RamanS. KhanA.A. MahmoodS. Nose to brain delivery of selegiline loaded PLGA/lipid nanoparticles: Synthesis, characterisation and brain pharmacokinetics evaluation.J. Drug Deliv. Sci. Technol.20227710392310.1016/j.jddst.2022.103923
     [Google Scholar]
  106. DetholiaK. MohandasA. VariaU. JadejaM. KatariyaH. Development and optimization of ropinirole loaded self-nanoemulsifying tablets.Fut Jour of Pharma Sci2023916610.1186/s43094‑023‑00516‑x
     [Google Scholar]
  107. NasrM. Development of an optimized hyaluronic acid-based lipidic nanoemulsion co-encapsulating two polyphenols for nose to brain delivery.Drug Deliv.20162341444145210.3109/10717544.2015.109261926401600
     [Google Scholar]
  108. KottaS. AldawsariH.M. Badr-EldinS.M. NairA.B. KaleemM. DalhatM.H. Thermosensitive hydrogels loaded with resveratrol nanoemulsion: Formulation optimization by central composite design and evaluation in MCF-7 human breast cancer cell lines.Gels20228745010.3390/gels807045035877535
     [Google Scholar]
  109. SalamaA. SolimanG.M. ElsherbinyN. SafwatM.A. Chitosan-coated nanoemulsion for the direct nose-to-brain delivery of sildenafil: Development and in vivo evaluation in a brain oxidative stress and inflammation model.J. Drug Deliv. Sci. Technol.20249810584210.1016/j.jddst.2024.105842
     [Google Scholar]
  110. AshharM.U. KumarS. AliJ. BabootaS. CCRD based development of bromocriptine and glutathione nanoemulsion tailored ultrasonically for the combined anti-Parkinson effect.Chem. Phys. Lipids202123510503510.1016/j.chemphyslip.2020.10503533400967
     [Google Scholar]
  111. van den BroekS.L. ShalgunovV. HerthM.M. Transport of nanomedicines across the blood-brain barrier: Challenges and opportunities for imaging and therapy.Biomater. Adv.202214121312510.1016/j.bioadv.2022.213125
     [Google Scholar]
  112. KhaitanD. ReddyP.L. NingarajN. Targeting brain tumors with nanomedicines: Overcoming blood brain barrier challenges.Curr. Clin. Pharmacol.201813211011910.2174/157488471366618041215015329651960
     [Google Scholar]
  113. BorsL.A. ErdőF. Overcoming the blood–brain barrier. Challenges and tricks for CNS drug delivery.Sci. Pharm.2019871610.3390/scipharm87010006
     [Google Scholar]
  114. AnsariM.A. ChungI.M. RajakumarG. AlzohairyM.A. AlomaryM.N. ThiruvengadamM. PottooF.H. AhmadN. Current nanoparticle approaches in nose to brain drug delivery and anticancer therapy - a review.Curr. Pharm. Des.202026111128113710.2174/138161282666620011615391231951165
     [Google Scholar]
  115. SunC. DingY. ZhouL. ShiD. SunL. WebsterT.J. ShenY. Noninvasive nanoparticle strategies for brain tumor targeting.Nanomedicine20171382605262110.1016/j.nano.2017.07.00928756093
     [Google Scholar]
  116. EmadN.A. AhmedB. AlhalmiA. AlzobaidiN. Al-KubatiS.S. Recent progress in nanocarriers for direct nose to brain drug delivery.J. Drug Deliv. Sci. Technol.20216410264210.1016/j.jddst.2021.102642
     [Google Scholar]
  117. BahadurS. PardhiD.M. RautioJ. RosenholmJ.M. PathakK. Intranasal nanoemulsions for direct nose-to-brain delivery of actives for CNS disorders.Pharmaceutics20201212123010.3390/pharmaceutics1212123033352959
     [Google Scholar]
/content/journals/cnm/10.2174/0124054615343935240918053255
Loading
Intranasal Nanoemulsion: A Promising Approach for the Management of Parkinson’s Disease
Curr. Nanomater. 11, 36 (2026); https://doi.org/10.2174/0124054615343935240918053255
/content/journals/cnm/10.2174/0124054615343935240918053255
/content/journals/cnm/10.2174/0124054615343935240918053255
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): bioavailability; blood-brain barrier; Intranasal drug delivery; motor activity; nanoemulsions; Parkinson's disease

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test